Open AccessEffectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
Author(s) -
Dorota ZarębskaMichaluk,
Jerzy Jaroszewicz,
Magdalena Rogalska,
Diana Martonik,
Paweł Pabjan,
Aleksandra Berkan-Kawińska,
Beata Bolewska,
Barbara Oczko-Grzesik,
Dorota Kozielewicz,
Magdalena TudrujekZdunek,
Justyna Kowalska,
Anna MoniuszkoMalinowska,
Krzysztof Kłos,
Marta Rorat,
Piotr Leszczyński,
Anna Piekarska,
Joanna Polańska,
Robert Flisiak
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s322645
Subject(s) - tocilizumab , covid-19 , medicine , dexamethasone , retrospective cohort study , virology , rheumatoid arthritis , disease , infectious disease (medical specialty) , outbreak
The pathogenesis of coronavirus disease 2019 (COVID-19) is complicated, and in addition to antiviral therapy and combating coagulopathy, treatment should also include inhibition of the proinflammatory cytokines overproduction. The purpose of this study is to compare the effectiveness of tocilizumab (TCZ) and dexamethasone (DEX) administered alone or in combination in patients with severe COVID-19.